Raffaele Giusti· @oncoblogger · X·· 2 天前评分45
正文 · 机器翻译
我们可能是在放火，却只是试着用水枪去灭火。
管理皮肤毒性很重要。但我们有多大把握认为，我们的风险缓解策略足够充分，而且收益与危害的总体权衡仍然有利？
#ESMO26 #LungCancer #Amivantamab
8 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
2700RO按 Rapid oral 1: NSCLC, metastatic 对上
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.orgNCT06385080NCT06385080按 - **标题 / Title：** A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer 对上
- **标题 / Title：** A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
https://esmocongress.esmo.orgNCT07276399NCT07276399按 - **标题 / Title：** A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer 对上
- **标题 / Title：** A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
https://esmocongress.esmo.org来源：Raffaele Giusti · x.com